IRCT20200105046010N45Recruiting未知
In- Vivo Bioequivalence study of Bicalutamide tablet 150 mg Sobhan Oncology (Bicalutamide 150mg) with brand drug (CASODEX® 150 mg AstraZeneca ) in Iranian healthy volunteers
Sobhan Oncology Pharmaceutical CO.0 sites24 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 24
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 60 years (—)
- Sex
- All
Inclusion Criteria
- •General health
- •Body mass index between18-28
- •Informed consent
- •Being at the age of 18-60 years old
Exclusion Criteria
- •History of cardiovascular disease
- •History of liver or kidney disease
- •Alcohol & Drug addiction
- •History of hypersensitivity
Investigators
Similar Trials
Not yet recruiting
Unknown
Bioequivalence study of Bicalutomide 50 mgIRCT20220111053692N15Iran Hormone pharmaceutical Co.24
Completed
Not Applicable
A clinical study of generic drug of bicalutamide on the efficacy and the safety in prostate cancer patientsProstate cancerJPRN-UMIN000005630Biwako health and welfare consortium60
Completed
Not Applicable
Comparative fasting bioavailability of 2 different betahistine dihydrochloride 24-mg tablets: a single-dose, randomized-sequence, open-label, 2-period crossover study in healthy Thai volunteers.healthy volunteersbetahistine dihydrochlorideBioequivalenceTCTR20151106002Somruedee Chatsiricharoenkul24
Terminated
Phase 1
Bioequivalence of Bicalutamide New Formulation in JapanHealthyNCT01416870AstraZeneca102
Not yet recruiting
Not Applicable
enalidomide tablet 25mg ABIDI (MYLODEQ® 25mg), In-Vivo Bioequivalence in iranian healthy volunteer, In-Vivo Bioequivalence in iranian healthy volunteerIn this study the bioequivalence of test and brand of Lenalidomide tablet will evaluated..IRCT20200105046010N6Tabriz University of Medical Sciences24